Competitive differentiation of VAL-083 as a treatment alternative in non-small cell lung cancer (NSCLC)

Non-small cell lung cancer is the leading cause of cancer deaths worldwide. Resistance to treatments results in a very poor long-term prognosis. VAL-083 is a chemotherapeutic drug that has activity against lung cancer in cell-studies and in clinical trials. It may be an effective treatment option for drug-resistant lung cancer. However, the detailed mechanism of VAL-083 activity in cancer cells is still unclear. The proposed internship project aims to determine the mechanism and resulting effects of VAL-083 in lung cancer cells. Understanding the mechanism allows DelMar to identify cancer patients who will benefit the most from VAL-083 treatment. It further aids DelMar in combining VAL-083 with other drugs to obtain maximum efficacy in lung cancer patients.

Faculty Supervisor:

Mads Daugaard

Student:

Partner:

Del Mar Pharmaceuticals Ltd

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

The University of British Columbia

Program: